Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivir To Acquire BioPhausia's Commercial Platform To Market HCV Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Medivir has a made a bid for BioPhausia in order to use the company as a commercial platform from which to market its hepatitis C drug, TMC435. Medivir sees the matter as urgent, as its drug is two years behind the competition.

You may also be interested in...



Sweden’s Medivir Prepares For Simeprevir And Profitability

Swedish hepatitis specialist Medivir aims to start Nordic marketing of its oral therapy simeprevir in 2014 and start anew as a profitable biotech with expansion prospects.

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel